Formulation and evaluation of mefenamic acid sustained release matrix pellets by MOHAMED ABBAS IBRAHIM
Interest in pellets as dosage forms has been increasing continuously. Several thera-
peutic advantages could be achieved by using pellets as a drug delivery system, over the
single-unit regimen, such as less irritation of the gastrointestinal tract and a lowered risk
of side effects due to dose dumping (1). Additionally, technological advantages such as
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The objective of the study was to prepare mefenamic acid
(MA) sustained release matrix pellets and investigate the
formulation parameters affecting pellet attributes and drug
release in vitro. A mixer torque rheometer (MTR) was used
to characterize the rheological properties of wet mass used
in pellet formulation. Mefenamic acid pellets were pre-
pared by extrusion/spheronization techniques using mi-
crocrystalline cellulose (MCC) in combination with lac-
tose as pellet forming agents and water as the binding
liquid. Also, the prepared pellets were characterized for
their particle size and in vitro drug dissolution. The re-
sults revealed that the increase in lactose weight ratio to
MCC resulted in a significant reduction of both maxi-
mum torque and binder ratios, while the addition of 2 %
(m/m) polyvinyl pyrolidone (PVP) to MCC-lactose influ-
enced only the mean torque rather than the wetting liquid
(water). Particle size ranged from 945 to 1089 mm and had
small span values (0.56–0.67). Furthermore, an inverse re-
lation was observed between the rheological character of
pellet wet masses (expressed by peak torque) and in vitro
release rate. Increasing MA loading from 2.5 to 5 and 10 %
was accompanied by a decrease in dissolution rates. In
conclusion, properties of MA matrix pellets could be
successfully monitored by controlling the wet mass cha-
racteristics by measuring torque.
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better flow properties, a less friable dosage form, narrow particle size distribution, ease
of coating and uniform packing can be achieved with pellets. Mehta et al. (2) showed
that multi-unit dosage forms have gained considerable popularity over conventional single
units for controlled release technology. This is due to the rapid dispersion of pellets in
the gastrointestinal tract; they maximize drug absorption, reduce peak plasma fluctua-
tions and minimize potential side effects without lowering drug bioavailability. Pellets
also reduce variations in gastric emptying rates and overall transit times. Thus, intra and
inter-subject variability of plasma profiles, which are common with single-unit regimens,
are minimized.
Different authors have utilized pellets and granules as controlled drug delivery sys-
tem techniques, which do not involve organic solvents or coating, because of stringent
global requirements for product safety. As the level of understanding the toxic effects of
these solvents is increasing, industrial hygiene rules and FDA regulations are being tigh-
tened worldwide, limiting the use of and exposure of workers to these solvents. Further-
more, the attempt to track and optimize the pellet coating process is rather difficult. Also,
by developing a matrix sustained release system one can save time and money by omit-
ting the coating operation. Monitoring the coating process by determining the amount of
drug or color deposited is tedious, and often leads to large variability (3). Hence, many
reports have been published on alternative techniques such as melt granulation (4), melt
extrusion (5–6), melt dispersion (7), and melt solidification (8) for controlled drug deli-
very systems. In addition, several attempts have been made to modify drug release from
multi-particulate oral dosage forms by incorporating various hydrophobic materials into
the basic formulation for pellets (9). Such systems retard the penetration of aqueous fluids
into the formulation and thereby slow the rate of drug release.
It has been shown that the rheological properties of wet masses can be successfully
monitored by means of a mixer torque rheometer (10–11). It was shown that the rheo-
logical properties of wet mass could affect the release patterns from pellet formulations.
Mahrous et al. (12) have observed that an inverse relationship exists between indometha-
cin release from the pellets and the peak torque values of the used polymer mixture.
Mefenamic acid (MA) [2-(2,3-dimethylphenyl)aminobenzoic acid], an anthranilic
acid derivative, is a nonsteroidal anti-inflammatory (NSAI), antipyretic, and analgesic
agent that is used for the relief of postoperative and traumatic inflammation and swel-
ling, antiphlogistic and analgesic treatment of rheumatoid arthritis, and antipyretic in
acute respiratory tract infection (13).
Mefenamic acid solubility in water is 0.04 mg mL–1 (14). Mefenamic acid is rapidly
absorbed after oral administration. Following a single 1 gram oral dose, mean peak plas-
ma levels ranging from 10 to 20 mg mL–1 have been reported. Peak plasma levels are
attained in 2 to 4 hours and the elimination half-life approximates 2 hours (15). The short
biological half-life of 2 h following oral dosing necessitates frequent administration of
the drug in order to maintain the desired steady state levels (16).
Moreover, dosage regimens involving conventional oral dosage forms require drug
administration three or four times daily to maintain adequate therapeutic effectiveness,
with inherent problems associated with patient compliance. In addition, conventional do-
sage forms do not protect patients against morning joint stiffness common in rheumatoid
disease states (17). Thus the development and clinical use of sustained or controlled relea-
se dosage forms of NSAIDs may have several advantages over the use of conventional
formulations, such as reduction of side effects, prolongation of drug action and impro-
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vement of bioavailability and patient compliance (18). Therefore, the formulation of MA
as sustained release dosage form matrix pellets could be an alternative approach to
overcome the potential problems in the gastrointestinal tract, in addition to minimizing
dosing frequency (19–20).
The present study is aimed at formulating sustained release matrix pellets loaded
with mefenamic acid using the extrusion/spheronization technique as an alternative to
the coating technique. Pellet wet masses were characterized using mixer torque rheometry
and also the impact of wet mass peak torque on the in vitro release rate of the drug load-
ed pellets was assessed.
EXPERIMENTAL
Materials
Mefenamic acid was kindly supplied by Al-Jazeera Pharmaceutical Industries (Ri-
yadh, KSA). Lactose monohydrate was purchased from Winlab (UK). Polyvinyl pyrro-
lidone (PVP K30) was purchased from Fluka (Switzerland). Microcrystalline cellulose,
MCC (Avicel® PH101) was purchased from Serva Feinbiochemica (Germany). All other
materials and solvents used were of reagent or analytical grade and were used without
further purification.
Characterization of pellet wet masses using a mixer torque rheometer
The mixer torque rheometer used in the present study consists of a 135-mL capacity
stainless steel bowl equipped with two mixing blades with rotational speed ranging be-
tween 20 and 150 rpm (MTR-3, Caleva, England). Depending on the bulk density, a
sample of 15–30 g of dry powder material is sufficient to cover the mixer blades. The
torque is measured directly at the mixer bowl with the help of a torque arm connected
from the main body of the mixer to a calibrated load transducer. The following equip-
ment settings were used for all the studies: mixer speed, 50 rpm. Data acquisition and
analyses were carried out with a personal computer using the data acquisition system
and software package supplied by the equipment manufacturer.
Powders were mixed in a turbula mixer (type S27, Erweka, Apparatebau, Germany)
and a 15-gram sample of this dry blend was utilized in the wet massing studies. Two
milliliters of granulating fluid were added in multiple additions over 15 wet massing
intervals. Each wet massing interval consisted of a one minute mixing period and a 20-
-second torque data logging (collection) period with the MTR operating at 50 rpm. Mean
torque was monitored during the granulation process.
Manufacture of pellets
Water was used as a granulating liquid in the manufacture of MA-loaded pellets.
The water volume required for wet massing was selected according to the highest torque
value measured by the rheometer. Compositions of different pellet formulations are shown
in Table I. MA and pellet excipients were mixed in a turbula mixer at certain weights
and the powder mixture was wetted with water. Next, the resulting wet mass was ex-
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truded at a speed of 90 rpm with a screen pore size of 1 mm (Mini Screw Extruder,
Model MSE1014, Caleva, England). Spheronization was performed in a spheronizer (Mo-
del 120, Caleva, England) with a rotating plate of regular cross-hatch geometry, at a speed
of 700 rpm, for 5 minutes. Pellets were then dried on a tray in a hot oven at 50–60 °C for
6 hours.
Drug content
Mefenamic acid (MA) content of the manufactured pellets was determined spectro-
photometrically at 285 nm in triplicate. Pellets were crushed in a porcelain mortar and
about 25 mg of the crushed pellets was dispersed in 250 mL of phosphate buffer (pH 6.8)
under sonication for 5 minutes. The supernatant was filtered through a cellulose nitrate
filter with pores of 0.2 mm in diameter (Sartorius, Germany) and measured spectropho-
tometrically (UV-2800 spectrophotometer, Labomed Inc., USA); MA content was then
calculated using a pre-constructed calibration curve.
Morphological analysis
Morphological characteristics of particles were observed by scanning electron mi-
croscopy (SEM). The samples were sputter-coated with a thin gold palladium layer un-
der an argon atmosphere using a gold sputter module in a high-vacuum evaporator.
Coated samples were then scanned and photomicrographs were taken with an SEM (Jeol
JSM-1600, Japan).
Particle size analysis
The size distribution of the manufactured pellets was investigated using laser light
diffraction (Mastersizer Scirocco 2000, Malvern Instruments, UK). For a typical experi-
ment, about 300 mg of pellets were fed in the sample micro feeder. All samples were an-
alyzed 5 times and average results were taken. The pellets of 10th (d(0.1)), 50th (d(0.5))
and 90th (d(0.9)) percentage were used to characterize the pellet size distribution. The
approximate mean diameter was taken as the average of d(0.1), d(0.5), and d(0.9) values.
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M1 M2 M3 M4 M5 M6 M7 M8 M9 M10
MCC 93 83 73 43 95 85 75 45 47.5 40
Lactose – 10 20 50 – 10 20 50 50 50
PVP K 30 2 2 2 2 – – – – – –
MA 5 5 5 5 5 5 5 5 2.5 10
Water q.s.
The span value was employed to characterize the pellet size distribution, since a










In vitro dissolution studies
Dissolution measurements were performed using an automated dissolution tester
(LOGAN Instrument Corp., USA) coupled to an automated sample collector (SP-100
peristaltic pump, USA). The USP dissolution basket method (apparatus 1) was used. MA
loaded pellets equivalent to 25 mg MA were added to 500 mL of dissolution medium
(phosphate buffer, pH 7.4). The temperature was maintained at 37 ± 0.5 °C. An accurately
weighed amount of the prepared pellets was added to each flask. For each sample for-
mula, drug dissolution was run in triplicate and absorbance was recorded automatically
at 285 nm up to 8 h. The percentage of drug dissolved was determined as a function of
time.
Statistical analysis
The results were analyzed using the software GraphPad Prism5 (GraphPad Soft-
ware, La Jolla, USA) applying one-way ANOVA. Differences between formulations were
considered to be significant at p £ 0.05.
RESULTS AND DISCUSSION
Wet massing studies
Wet massing experiments were performed for MCC-lactose-PVP systems in order to
establish the water/powder ratio needed to reach a maximum torque response. For the
MCC-lactose systems, Fig. 1, different liquid saturation phases (pendular, funicular and
capillary) were passed through, with the maximum torque occurring at the capillary state.
MCC system exhibited a typical progression of liquid saturation phases. The mean torque
value was found to increase with an increase in wet massing liquid (water). However,
different profiles were detected regarding MCC-lactose systems in which the increase of
lactose weight resulted in a significant reduction of the area of MTR curve, i.e., progres-
sion of liquid saturation phases occurred at lower water/powder ratio. In addition, re-
ductions of peak torque water/powder ratios (mL g–1) and peak torque magnitudes were
recorded, with the lowest value (0.156 N m) at the 50 % (m/m) lactose level, Fig. 1. Rheo-
logical behaviors of MCC-lactose systems containing 2 % (m/m) PVP (Fig. 2) are quite
different when compared to MCC-lactose systems. Addition of 2 % (m/m) PVP to this pow-
der mixture influenced only the maximum torque rather than water volume at maximum
torque. The degree of liquid spreading and wetting as well as the substrate-granulating
89
M. A. Ibrahim: Formulation and evaluation of mefenamic acid sustained release matrix pellets, Acta Pharm. 63 (2013) 85–98.
liquid interaction will determine the relative positions of peak values of the mean line
torque (22). In addition, the pendular and funicular states are characterized by a pro-
gressively increasing network of liquid bridges. Both of these stages will cause an in-
crease in cohesiveness of the powder mass and hence an increased torque on the mixer
(23–24). The capillary state which is reached when all air spaces in the granular material
are filled with liquid occurs at the maximum on the curve. With further addition of liq-
uid, the torque decreases as a slurry of particles dispersed in liquid is formed.
Pellets sizes and shapes
The volume weighted mean particle size and the d(0.1), d(0.5) and d(0.9) values of
different pellet formulae loaded with MA, as determined by laser diffractometry, are list-
ed in Table II. In general, the volume weighted mean of the manufactured pellets was
found to be in a range from 945 to 1089 mm. In addition, the particle size distribution of
MA sustained release matrix pellets was characterized by small span values. Calculated
span values for all pellet formulations were found to be 0.56–0.67, indicating a narrow
particle size distribution (25).
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Fig. 1. Effect of different concentrations of lactose on mean torque for MCC PH101: 0 (•), 10 % (n),
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Fig. 2. Effect of different concentrations of lactose on mean torque for Avicel PH101 containing 2 % PVP:
0 (•), 10 % (n), 20 % (p) and 50 % (¡).
Scanning electron micrographs of some sustained release MA matrix pellet formula-
tions (M4, M8 and M9) are displayed in Figure 3. The prepared pellet formulas F8 and
F9 appear almost rounded and intact in shape, while M4 pellets are not completely
spherical. This might be due to the higher mean torque value of the wet mass of formula
M4 (0.445 N m) compared to the lower torque value of formula M8 (0.156 N m). These
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Table II. Volume weighted mean particle size and the d(0.1), d(0.5), d(0.9) and span values of different
pellet formulae loaded with MA (5 % (m/m) as determined by laser diffractometry)
Pellet formulae Mean d(mm) d(0.1) (mm) d(0.5) (mm) d(0.9) (mm) Span value
M1 1027.11 760.59 1065.27 1471.1 0.67
M2 1016.86 762.99 1049.44 1415.72 0.62
M3 944.95 710.58 973.86 1337.41 0.64
M4 1080.23 825.78 1113.51 1479.38 0.59
M5 1045.12 690.10 984.19 1398.10 0.72
M6 1005.18 675.14 915.48 1218.4 0.59
M7 993.10 750.23 1020.39 1388.95 0.63
M8 999.83 737.30 1041.90 1435.65 0.67
M9 1034.89 791.22 1062.04 1412.97 0.59
M10 1089.15 825.14 1087.45 1428.10 0.56
Fig. 3. Scanning electron micrographs of: a) pellets, b) pellet surfaces.
results are in accord with the data obtained by Mahrous et al. (12), who showed that the
more hydrophilic polymer (PEG 4000), when mixed with MCC, produced a wet mass
having the lowest mean torque value compared to that recorded with the same weight
ratio of PVP and HPMC. This in turn reflects on the easy extrusion of the PEG wet mass,
resulting in pellets with smoother surfaces. In addition, Law and Deasy (26) reported that
the use of hydrophilic polymers with MCC favored more spherical and smooth pellets.
In vitro release studies
Pellet drug content was calculated before in vitro dissolution studies. The obtained
data showed that MA content ranged from 95 to 105 % of the theoretical content, indi-
cating homogenous drug distribution in the prepared pellets.
Apart from influencing the yield and sphericity of the product, addition of excipients
such as CMC and lactose could also affect drug release. Mixes of various hydrophilic
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polymers with MCC (1:19) were reported previously by Law and Deasy (26) to aid extru-
sion-spheronization and, at the same time, to enhance the dissolution of indomethacin.
The in vitro release data of MA from pellet formulations are displayed in Fig. 4. It
can be seen that untreated MA was completely released in less than 90 minutes. Incorpo-
ration of the drug in pellet formulations containing PVP (M1-M4) resulted in slowing its
release rate in dependence on the weight of the hydrophilic additive (lactose) in the for-
mula. Increasing lactose weight was accompanied by an enhancement of the drug release
rate. For example, about 75 % of incorporated MA was released from the pellet formula
containing 50 % lactose (M4), while only 63 % was releaseed from the pellet formula
containing only 10 % lactose (M1). Lactose enhances the drug release rate by forming
pores and it also promotes water penetration into the formulation core. In addition, in-
creasing the lactose concentration caused a pronounced lowering of the mean torque of
pellet wet mass before extrusion/spheronization procedures. The in vitro release of MA
from pellet formulations that do not contain PVP (M5-M8) is illustrated in Fig. 4b. The
results revealed that MA exhibited a faster release pattern from pellet formulas that con-
tain MCC and lactose compared to the pellets made by blending these excipients with
PVP. Similarly, a pronounced enhancement of MA release from formulae M5 to M8 was
a result of increased lactose weight, especially for formulae M7 and M8 containing 20
and 50 % lactose, respectively. The dependence of MA release rate from these pellet for-
mulations could be explained on the basis of the inverse relationship between the release
rate (represented by % MA release after 480 min) and the peak torque values of the pellet
wet mass, as shown in Fig. 5. Ibrahim et al. (27) found an inverse relationship between
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Fig. 5. Correlation between the pellet wet mass peak torque and the percent of mefenamic acid re-
leased after 480 minutes from a) M1-M4 formulae and b) M5-M8 formulae (mean ± SD).
indomethacin release from its loaded pellets and the peak torque values of the polymer
mixed with co-solvents.
The effect of pellet wet masses peak torque on the calculated Higuchi diffusion slope
(% MA released min–0.5) is illustrated in Fig. 6. Inverse proportionality between the peak
torque and MA diffusion rate was pronounced in the systems containing MCC and lac-
tose only (formulas M5-M8), Fig. 6b. However, in pellet formulations containing PVP
(formulas M1-M4), a slight retarding action of wet mass peak torque on the Higuchi dif-
fusion slope was observed, Fig. 6a.
The effect of MA loading on the in vitro drug release from a selected pellet formula
(M8) is shown in Fig. 7. It is clearly evident that increasing MA concentration in the pellet
formula resulted in retardation of its release rate. For example, MA showed complete
release from the pellet formula containing 2.5 % drug (M9), while only 73 % was releas-
ed from the formula containing 10 % MA (M10). This might be explained by the assump-
tion that increasing the concentration of the poorly soluble drug will decrease the con-
tent of the hydrophilic excipient lactose. Similar findings were observed by Zhou et al.
(28), who showed that the decrease of ibuprofen release from matrix pellets at higher
drug concentrations was due to a decrease in starch content. This results in a reduction
of hydrophilic pathways for water molecules to access drug crystals inside the pellet.
The same phenomenon was also observed by Adeyeye and Price (29).
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Fig. 6. Correlation between the pellet wet mass peak torque and the Higuchi diffusion slope calcu-
lated for: a) M1-M4 formulae, b) M5-M8 formulae.
a)
b)
Kinetic modeling of in vitro release of MA from matrix pellets
The in vitro release data of MA from different sustained release matrix pellets were
fitted using the zero order, first order and Higuchi diffusion models as well as the Kors-
meyer-Peppas equation to determine the model that best describes drug release from
pellet formulations. Preference of the release mechanism is based on the value of the cor-
relation coefficient. The data revealed a good fit to the Korsmeyer-Peppas equation, indi-
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M9 (2.5 % MA)
M8 (5 % MA)
M10 (10 % MA)
Fig. 7. Effect of different mefenamic acid concentrations on in vitro release profiles from pellet for-
mulation M8 (mean ± SD).












M1 0.930 0.960 0.990 0.990 0.56
M2 0.888 0.949 0.979 0.983 0.43
M3 0.926 0.971 0.991 0.991 0.51
M4 0.928 0.978 0.992 0.989 0.53
M5 0.887 0.928 0.978 0.989 0.4
M6 0.887 0.928 0.978 0.989 0.39
M7 0.939 0.995 0.996 0.995 0.49
M8 0.929 0.990 0.993 0.993 0.50
M9 (M8 + 2.5 % MA) 0.920 0.988 0.991 0.990 0.47
M10 (M8 + 10 % MA) 0.934 0.980 0.994 0.992 0.52
R – correlation coefficient; n – the release exponent obtained from Korsmeyer-Peppas equation
cating combined effects of diffusion and erosion mechanisms for drug release (30). In ad-






The data displayed in Table III showed that the calculated values of n were lower
and higher than 0.45, but all were less than 1, indicating also non-Fickian or anomalous
drug release or the so called coupled diffusion/polymer relaxation. Moreover, slight
swelling and erosion of the pellet matrix were observed for the manufactured matrix
pellets, and the pellets did not disintegrate in the dissolution medium even after 8 hours.
It has been concluded by several authors that when liquid diffusion rate and polymer re-
laxation rate (erosion) are of equal magnitude, anomalous or non-Fickian diffusion is ob-
served (30, 32).
CONCLUSIONS
In conclusion, the properties of MA matrix pellets could be successfully correlated
with the wet mass characteristic using mixer rheometry. This will help obtain a control-
led release dosage form capable of lowering the risk of side effects and improving pa-
tient convenience as an advantage of pellets as a drug delivery system.
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